Prostate Cancer Progression and Serum SIBLING (Small Integrin Binding N- Linked Glycoprotein)Levels

摘要

We have been studying a gene family termed SIBLINGs (for small integrin binding ligand N-linked glycoproteins) whose members include bone sialoprotein (BSP), osteopontin (OPN), dentin matrix protein-1 (DMP1), dentin sialophosphoprotein (DSPP) and matrix extracellular phosphoglycoprotein (MEPE). Our Specific Aims are to describe the distribution of serum-based measurements of SIBLINGs among (a) normal individuals, (b) individuals with benign prostatic disease, (c) individuals with clinically defined prostate cancer, and (d) longitudinal samples from individuals with prostate cancer before and after treatment; and to establish serum-based measurements which maximize sensitivity and specificity of SIBLINGs as markers for prostate cancer detection as well as for prostate cancer progression and response to treatment. Although the laboratory is still blinded to staging and progression data at this point in time, some significant observations can be made. The distribution of serum levels of BSP and DSPP suggest they have utility for prostate cancer detection. Whether used separately or as an adjunct to PSA screening, the preliminary data indicates that measurement of SIBLINGs will have a significant effect on current prostate cancer management.